Fox Rothschild's Marc Wagner on how 503A pharmacies and 503B outsourcing facilities fill drug supply gaps — from COVID injectables to GLP-1s.
|Articles|December 10, 2015
Special Section Media, Communications & Social Media
Author(s)DIA
Advertisement
From enhancing the clinical trial recruitment process to providing a powerful tool for communicating drug safety, mobile technology and social media are quickly becoming part of the biopharmaceutical landscape. This Special Section of the December 2015 Global Forum explores the intersection of digital technology with the patient experience, and showcases forward-thinking applications of technology into the drug development process.
To read this article,
Advertisement
Related to this article
Experts warn prediction markets are exposing gaps in pharma vendor confidentiality agreements, Roche licenses Rona Therapeutics’ obesity RNAi candidate while Pfizer partners with Enodia Therapeutics on Sec61 inhibitors, and PaxSafe’s Mark Talens makes the case for acting on imperfect supply chain data.
Roche licenses Rona Therapeutics’ ALK7-targeting RNAi candidate for obesity, while Pfizer partners with Enodia Therapeutics on Sec61 inhibitor discovery.
As CROs, labs, and other outside partners gain early access to trial and FDA data that sponsor employees have, experts say closing the gap starts with rewriting confidentiality language.
Fox Rothschild's Marc Wagner on why scaling drug production is so slow — overseas API sourcing, supplier qualification, and FDA site approvals that take years.
PaxSafe's Mark Talens on why pharma supply chain AI fails before it starts — and the data foundry framework that changes that.
Thomas Appio has been named interim CEO of Bausch + Lomb, a move coinciding with an expected upward revision to the company’s full-year guidance.
A conversation with Geoffrey T. Sanzenbacher, a research fellow at the Center for Retirement Research.
Advertisement
Advertisement
Trending on PharmExec
1
Prediction Markets Expose a Gap in Pharmaceutical Vendor Contracts
2
Roundup: Rona Therapeutics Enters Global License Agreement for ALK7-targeting RNAi Therapy, Enodia Therapeutics Enters Collaboration and License Agreement to Develop Sec61-Targeting Small Molecules
3
The Bottlenecks That Slow Manufacturer Response to Increased Demand for Production
4
Pharmaceutical Executive Daily: Rona Therapeutics Enters Global License Agreement for ALK7-targeting RNAi Therapy with Roche
5